Discounted Cash Flow
Pacira Biosciences, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $276.4m | $-37.9m | $8.7m | -13.7% | $-1.02 |
| 2017 | $286.6m (3.7%) | $-42.6m (-12.3%) | $-1.5m (-116.9%) | -14.9% (-8.3%) | $-1.07 (-4.9%) |
| 2018 | $332.4m (16.0%) | $-471.0k (98.9%) | $34.4m (2419.8%) | -0.1% (99.0%) | $-0.01 (99.1%) |
| 2019 | $418.9m (26.0%) | $-11.0m (-2238.9%) | $60.4m (75.7%) | -2.6% (-1755.9%) | $-0.27 (-2600.0%) |
| 2020 | $426.6m (1.8%) | $145.5m (1421.0%) | $39.2m (-35.0%) | 34.1% (1397.2%) | $3.41 (1363.0%) |
| 2021 | $539.0m (26.3%) | $42.0m (-71.2%) | $79.9m (103.5%) | 7.8% (-77.2%) | $0.95 (-72.1%) |
| 2022 | $666.8m (23.7%) | $15.9m (-62.1%) | $115.2m (44.3%) | 2.4% (-69.4%) | $0.35 (-63.2%) |
| 2023 | $675.0m (1.2%) | $42.0m (163.7%) | $139.5m (21.1%) | 6.2% (160.5%) | $0.91 (160.0%) |
| 2024 | $1.4b (107.1%) | $-99.6m (-337.3%) | $178.8m (28.1%) | -7.1% (-214.6%) | $-2.15 (-336.3%) |
| 2025 | $726.4m (-48.0%) | $7.0m (107.1%) | $136.7m (-23.5%) | 1.0% (113.6%) | $0.16 (107.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.